TP53 and neoplasm: Unexpectedly, the p38 MAPK-mediated anti-tumor effect did not appear to proceed through wt-p53 activation, as canonically reported [34] and, indeed, p38 MAPK inhibition protected from oxaliplatin exposure even in CRC cell lines lacking p53 functionality [35].